US drugmaker Merck stated that its CEO Ken Frazier plans to testify at a Senate hearing Tuesday, February 26.
Republican Senator Chuck Grassley, chairman of the Senate Finance Committee, and Democratic Senator Ron Wyden, ranking member of the committee invited executives from seven pharmaceutical companies, including Merck, to testify. The others are AbbVie, AstraZeneca, Bristol-Myers Squibb, Johnson & Johnson, Pfizer, and Sanofi.
Congress has been targeting the pharmaceutical industry over the rising cost of prescription drugs for US consumers, particularly since Democrats took over the House of Representatives in January.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
PepsiCo Sued Over Alleged Price Discrimination Involving Walmart
Jan 19, 2025 by
CPI
Regulators Approve Conditions for Multibillion-Dollar Oil Mergers
Jan 19, 2025 by
CPI
FTC Reaches Settlement with Private Equity Firm Over Antitrust Allegations in Texas
Jan 19, 2025 by
CPI
FTC Raises Antitrust Concerns Over Big Tech’s AI Partnerships
Jan 19, 2025 by
CPI
MultiPlan and Insurers Move to Dismiss Antitrust Allegations Amid Growing Legal Challenges
Jan 19, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – CRESSE Insights
Dec 19, 2024 by
CPI
Effective Interoperability in Mobile Ecosystems: EU Competition Law Versus Regulation
Dec 19, 2024 by
Giuseppe Colangelo
The Use of Empirical Evidence in Antitrust: Trends, Challenges, and a Path Forward
Dec 19, 2024 by
Eliana Garces
Some Empirical Evidence on the Role of Presumptions and Evidentiary Standards on Antitrust (Under)Enforcement: Is the EC’s New Communication on Art.102 in the Right Direction?
Dec 19, 2024 by
Yannis Katsoulacos
The EC’s Draft Guidelines on the Application of Article 102 TFEU: An Economic Perspective
Dec 19, 2024 by
Benoit Durand